Thuasne Invests €4M in Personalized Post-Cancer Care in Saint-Étienne

Saint-Étienne, France is poised to become a hub for innovative post-cancer care, as medical device company Thuasne announced a €4 million investment to develop personalized healing solutions. The project, a collaboration with the University Jean Monnet and supported by the French State and the Auvergne-Rhône-Alpes region, aims to address the needs of an estimated 200,000 patients in France and a potential global market of 250 million individuals.

A Focus on Personalized Post-Cancer Care

Thuasne, a specialist in medical devices, confirmed the investment will focus on an innovative project dedicated to health post-cancer treatment. The core objective is to tailor patient care to individual circumstances, working closely with researchers, and clinicians. The University Jean Monnet of Saint-Étienne is a key partner, alongside public funding from the State and the Auvergne-Rhône-Alpes region.

Did You Know? Thuasne employs 2,500 people in Saint-Étienne as of 2026.

This project is deeply rooted in the local Saint-Étienne community, leveraging the company’s existing presence and expertise. According to a company statement, the initiative will “combine industrial expertise and academic research for more effective solutions.” The Auvergne-Rhône-Alpes region has also emphasized its commitment to medical innovation and the future of healthcare.

Potential for Future Advancements

Initial results from the project are anticipated in the coming months, with potential benefits for both patients and the local medical ecosystem. The development centres around a digitalized, dynamic compression solution integrating motorized pressure on the affected limb.

Expert Insight: This investment signals a growing trend toward more individualized and technologically advanced approaches to post-cancer care, potentially improving quality of life for a significant number of patients.

Frequently Asked Questions

What is the primary goal of Thuasne’s investment?

The primary goal is to develop a solution of compression dynamic digitalisée to improve the care of patients suffering from post-cancer lymphoedema.

Who are the key partners in this project?

The key partners include the University Jean Monnet of Saint-Étienne, the French State, and the Auvergne-Rhône-Alpes region.

How many patients could potentially benefit from this project?

The project aims to address the needs of 200,000 patients in France and a potential global market of 250 million individuals.

As Thuasne moves forward with this ambitious project, what role do you see technology playing in the future of post-cancer care?